Detection of AD Biomarkers in Tear Fluid

Completed

• Conditions: Cognitive Impairment
• Interventions: Other: Tear sampling

• Registration Number: NCT04620902
• Lead Sponsor: Maastricht University Medical Center

Brief Summary

Detection of AD biomarkers in tear fluid

Detailed Description

Not available

Study Timeline

• Study Start: 2018-01-01
• Primary Completion: 2020-01-01
• Study Completion: 2020-01-01
• Status Verified: 2020-11
• Study First Submitted: 2020-11-03
• Study First Submitted QC: 2020-11-03
• Last Update Submitted: 2020-11-03
• Study First Posted: 2020-11-09
• Last Update Posted: 2020-11-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 69

Inclusion Criteria

• . Inclusion criteria were an MMSE score ≥ 20 and a CDR score from 0 to 1, thereby including patients across the whole clinical spectrum (i.e. from subjective cognitive disorder to (mild) dementia).

Exclusion Criteria

• Exclusion criteria at baseline were neurological diseases (such as Normal Pressure Hydrocephalus, Morbus Huntington, brain tumor, epilepsy, encephalitis, recent Transient Ischemic Attack (TIA) or cerebrovascular accident (CVA) (< 2 years), or TIA/CVA with concurrent (within three months) cognitive decline) and a history of psychiatric disorders (such as schizophrenia, bipolar disorder or psychotic problems, current major depressive disorder (within 12 months), or alcohol abuse).

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
SCD	Tear sampling	Subjective cognitive decline
Dementia	Tear sampling	Dementia
MCI	Tear sampling	Mild cognitive impairment
HC	Tear sampling	Cognitively healthy control

Primary Outcome Measures

Name	Time	Method
Level of AD biomarkers in tear fluid	Baseline

Trial Locations

Locations (1)

Academic Hospital Maastricht; 🇳🇱 Maastricht, Netherlands